检索临床试验

本研究将评估其疗效, 安全, 在胃或胃食管交界(GEJ)腺癌患者中，TRK-950联合ramucirumab和紫杉醇(RAM+PTX)两种单独剂量水平的最佳剂量、ADA和nab的发展，与单独使用RAM+PTX治疗相比.

这项首次人体研究将评估安全性, 耐受性, 药物动力学, and antitumor activity of TORL-4-500 in patients with advanced cancer

本研究的目的是评估RO7496353与检查点抑制剂(CPI)联合或不联合标准治疗(SOC)化疗对局部晚期或转移性实体肿瘤(如非小细胞肺癌(NSCLC))患者的安全性和耐受性。, 胃癌(GC)和胰导管腺癌(PDAC). The study will be conducted in 2 stages: an initial 安全 run-in stage and an expansion stage.

这项首次人体研究将评估安全性, 耐受性, 药物动力学, and antitumor activity of TORL-3-600 in patients with advanced cancer

The main purpose of the study is to evaluate the 安全 and 耐受性 of HRO761 and identify the recommended dose(s), i.e., HRO761单独或联合替利单抗或伊立替康的最佳安全和有效剂量，可以给予患有称为MSIhi(微卫星不稳定性高)或dMMR(错配修复缺陷)的特定分子改变的癌症患者，这可能最有效地治疗这些特定的癌症类型，并了解HRO761治疗这些癌症的效果.

这项临床试验的目的是测试CPO301, a type of drug called an antibody drug conjugate in adult patients with advanced or metastatic solid tumors.

它旨在回答的主要问题是:

• To assess the 安全 and 耐受性 of CPO301 at increasing doses and determine the dose to be used in the second part of the study (Part A)
• 在A部分中确定的剂量下，评估CPO301在非小细胞肺癌和其他潜在肿瘤类型患者中的安全性和耐受性(B部分)。
• To evaluate how quickly CPO301 is metabolized by the body (药物动力学 or PK)
• To evaluate if antibodies to the study drug develop (immunogenicity)
• 评价药物的初步疗效
• To correlate preliminary efficacy with mutations in a biomarker called EGFR

参与者将:

• 提供书面知情同意
• Undergo screening tests to ensure they are eligible for study treatment
• 参加所有要求的研究访问，每3周静脉注射一次CPO301，直到研究医生确定应该停止研究治疗, 基于参与者在治疗中的表现
• 每3个月随访一次病情进展，持续2年

这项研究正在研究一种新的化合物, AZD8205, 作为晚期或转移性实体瘤的可能治疗方法

这是一项剂量递增和剂量扩展的1/2a期试验，旨在评估DB-1305在晚期实体瘤患者中的安全性和耐受性.

The main aim of this study is to check if people with advanced solid tumors have 副作用 from dazostinag, 并检查在单独使用和与派姆单抗联合使用时，他们可以在没有明显副作用的情况下接受多少眩晕. The study will be conducted in two phases including a dose escalation phase and a dose expansion phase. 在剂量递增阶段, 递增剂量的dazoststing正在单独或联合pembrolizumab进行试验，以治疗晚期或转移性实体瘤患者. 在剂量膨胀阶段, dazostinag will be studied with pembrolizumab with or without chemotherapy in participants with untreated metastatic or recurrent, 不可切除的头颈部鳞状细胞癌(SCCHN)和pembrolizumab联合治疗三线或晚期复发性局部晚期或转移性微卫星不稳定性高/错配修复缺陷(MSI-H/dMMR)和三线复发性局部晚期或转移性微卫星稳定/错配修复良好(MSS/pMMR)结直肠癌(CRC).

这是第一次人体试验, 阶段1 b / 1, 多中心, 非盲, dose escalation study of STK-012 as monotherapy and in combination with pembrolizumab in patients with selected advanced solid tumors.

这项随机3期开放标签研究将比较t细胞免疫球蛋白和免疫受体酪氨酸抑制基序(ITIM)结构域(TIGIT)单克隆抗体domvanalimab的疗效, the anti programmed cell death protein 1 (PD-1) monoclonal antibody zimberelimab, 多药化疗与抗PD-1单克隆抗体nivolumab和多药化疗在局部晚期不可切除或转移性胃癌患者的一线治疗中的比较, 胃食管交界(GEJ), 还有食管腺癌.

来描述安全性, 耐受性, 药物动力学, 药效学, and preliminary anti-tumor activity of QEQ278 in adult patients with advanced/metastatic non-small cell lung cancer, 食管鳞癌, 肾细胞癌, and human papilloma virus associated head and neck squamous cell carcinoma.

The main purpose of this study is to learn more about the 安全, 副作用, LOXO-260的有效性. LOXO-260 may be used to treat cancer that has a change in a particular gene (known as the RET gene). Participation could last up to 24 months (2 years) and possibly longer if the disease does not get worse.

本研究的目的是评估局部晚期不可切除或转移性胃癌患者联合化疗和不联合化疗的安全性和初步临床活性, GEJ, 还有食管腺癌. Chemotherapy will consist of FOLFOX (oxaliplatin, 甲酰四氢叶酸, fluorouracil).

RBS2418 (investigational product) is a specific immune modulator, working through ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1), 通过增加内源性2'-3'-环鸟苷单磷酸腺苷(cGAMP)和三磷酸腺苷(ATP)水平，减少肿瘤中腺苷的产生，从而产生抗肿瘤免疫. RBS2418 has the potential to be an important therapeutic option for subjects both as monotherapy and in combination with checkpoint blockade. 这项研究是开放标签的, RBS2418的多位点1a/1b期研究, 选择性ENPP1抑制剂, in combination with pembrolizumab or as a monotherapy in subjects with advanced unresectable, 复发或转移性肿瘤.

拟议的研究旨在检查AZD0171和durvalumab联合标准治疗化疗对胰腺导管腺癌(PDAC)患者的影响。.

The main objective of this study is to compare efficacy of bemarituzumab combined with oxaliplatin, 甲酰四氢叶酸, FGFR2b≥10% 2+/3+肿瘤细胞染色(FGFR2b≥10% 2+/3+TC)患者的总生存期(OS)评估:5-氟尿嘧啶(5-FU) (mFOLFOX6)与安慰剂加mFOLFOX6

The main objective of Part 1 is to evaluate the 安全 and 耐受性 of bemarituzumab plus 5-fluorouracil, 甲酰四氢叶酸, 奥沙利铂(mFOLFOX6)和纳武单抗.

第2部分的主要目的是比较bemarituzumab联合化疗(mFOLFOX6或卡培他滨联合奥沙利铂(CAPOX))和纳武单抗与安慰剂联合化疗(mFOLFOX6或CAPOX)和纳武单抗的总生存期.